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The p53 tumor suppressor protein is a potent activator of proliferative arrest and cell death. In normal cells, this
pathway is restrained by p53 protein degradation mediated by the E3-ubiquitin ligase activity of MDM2. Oncogenic
stress releases p53 fromMDM2 control, so activating the p53 response. However,many tumors that retainwild-type
p53 inappropriately maintain the MDM2-p53 regulatory loop in order to continuously suppress p53 activity. We
have shown previously that single point mutations in the human MDM2 RING finger domain prevent the inter-
action ofMDM2with the E2/ubiquitin complex, resulting in the loss ofMDM2’s E3 activity without preventing p53
binding. Here, we show that an analogous mouse MDM2 mutant (MDM2 I438K) restrains p53 sufficiently for
normal growth but exhibits an enhanced stress response in vitro. In vivo, constitutive expression of MDM2 I438K
leads to embryonic lethality that is rescued by p53 deletion, suggesting MDM2 I438K is not able to adequately
control p53 function through development. However, the switch to I438K expression is tolerated in adult mice,
sparing normal cells but allowing for an enhanced p53 response to DNA damage. Viewed as a proof of principle
model for therapeutic development, our findings support an approach that would inhibitMDM2 E3 activity without
preventingMDM2/p53 binding as a promising avenue for development of compounds to activate p53 in tumorswith
reduced on-target toxicities.
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The p53 transcription factor is a critical regulator of the
cellular response to an extensive range of genotoxic, met-
abolic, and environmental stressors (Levine 2020). The
predominant activity of p53 is as a tumor suppressor,
and mutations in p53 or defects in the pathways leading
to the activation of p53 are the most frequent alterations
in cancer, contributing to the development of most tu-
mors (Kastenhuber and Lowe 2017).
Although p53 is ubiquitously expressed, it is restrained
from undue action by rapid turnover of the p53 protein.
Two related RING finger E3-ligase proteins, MDM2 and
MDMX (MDM4 inmice), act as the main negative regula-
tors of p53 stability (Karni-Schmidt et al. 2016; Moyer
et al. 2017). Both MDM2 andMDM4 are required to limit
p53 activity (Huang et al. 2011; Pant et al. 2011) and in
mice the deletion of either results in embryonic lethality
that is rescued by concomitant deletion of Trp53 (Jones
et al. 1995; Montes de Oca Luna et al. 1995; Parant et al.
2001). While deletion of Mdm2 is similarly fatal in adult
mice, again in a p53-dependent manner (Ringshausen
et al. 2006; Zhang et al. 2014), transient loss of Mdm4 is
tolerated in adult mice expressing wild-type p53, despite
the resulting induction of a p53 response (Garcia et al.
2011).
MDM2 and MDMX regulate p53 through a number of
mechanisms (Shadfan et al. 2012; Wang and Jiang 2012),
including an ability to direct p53 degradation (Haupt
et al. 1997; Honda et al. 1997; Kubbutat et al. 1997). In oth-
erwise unstressed cells, MDM2 is predominantly nuclear
and exists as either a homodimer or heterodimer, with a
second MDM2 molecule, or with MDMX. In either case,
it is the MDM2 RING finger domain that is essential for
the E3 ubiquitin ligase (E3) activity of either dimer to
ubiquitinate p53 and facilitate its proteasome-mediated4These authors contributed equally to this work.
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degradation, as MDMX does not possess intrinsic E3
activity (Linares et al. 2003; Iyappan et al. 2010). Indepen-
dent of degradation, the binding ofMDM2 to theN-termi-
nal transactivation domain of p53 can also directly inhibit
p53 activity by restricting the interactions between p53
and other transcriptional machinery (Momand et al.
1992; Oliner et al. 1993; Shi and Gu 2012). Additionally,
MDM2 E3 activity can indirectly limit p53 transcription-
al activity by ubiquitinating histones within promoters,
thereby blocking access for p53 and the transcriptional
machinery (Minsky and Oren 2004). The regulation of
p53 byMDM2 can therefore be divided into E3-dependent
and E3-independent actions that act coordinately to limit
the level and subsequent activity of p53 in unstressed
cells.
Signals that activate p53 lead to an array of responses
that function to block the ability of MDM2 to degrade
p53 (Karni-Schmidt et al. 2016). The subsequent accumu-
lation of active p53 allows the transcription of p53 target
genes to orchestrate the cellular stress response. Impor-
tantly, transcription of MDM2 itself is also activated by
p53, facilitating a self-limiting p53-MDM2 feedback
loop that brings p53 signaling back under control when
the initiating stress has resolved. In the 30%–50% of hu-
man cancers that retain wild-type p53, this loop is com-
promised, leading to a failure to properly restrain MDM2
and causing continuous limitation of p53 activity irre-
spective of activating signals (Wasylishen and Lozano
2016). Uncovering mechanisms that would lead to the re-
activation of the latent p53 in these tumors is an area of
therapeutic interest and has resulted in the development
of many compounds that block the MDM2-p53 interac-
tion (Cheok and Lane 2017). However, these compounds
have been of limited efficacy in clinical trials due to
dose-limiting on-target toxicities arising from p53-medi-
ated neutropenia and thrombocytopenia (Andreeff et al.
2016; Kastenhuber and Lowe 2017).
Previous studies have identified the RING domain and
C terminus of MDM2 as critical for E3 activity. The hu-
man MDM2 RING domain amino acid C464 is required
for MDM2 dimerization and for maintaining overall
RING domain structure (Honda and Yasuda 2000), while
the C-terminal tail of either MDM2 (in a homodimer) or
MDMX (in a heterodimer) are required to support ubiqui-
tin binding (Nomura et al. 2017). Mutation of residue
C464 (C462 inmouseMDM2) disrupts both E3-dependent
and E3-independent activities of MDM2 and leads to em-
bryonic lethality when expressed in mice (Itahana et al.
2007). Tail region mutations of MDM2 also inhibit the
E3 activity of a homodimer, but are active as a hetero-
dimer with wild-type MDMX (Poyurovsky et al. 2007;
Singh et al. 2007; Uldrijan et al. 2007). In vivo, expression
of a C-terminal tail mutant of MDM2 (Y487A) that is de-
fective for E3 activity as a homodimer but can be rescued
by wild-type MDMX did not impede embryogenesis, re-
flecting a retention of the ability to control p53 during de-
velopment (Tollini et al. 2014).
To examine the importance of complete loss of MDM2
E3 activity, we previously demonstrated that single point
mutations in the MDM2 RING finger domain at amino
acid I440 or R479 prevented the interaction of MDM2
with the E2/ubiquitin complex, resulting in the loss of
MDM2 E3 activity without otherwise disrupting the
structure of the MDM2 RING finger domain (Nomura
et al. 2017). Although these mutants retained the ability
to dimerize, they could not be rescued by interaction
with MDMX. Despite compromised E3 function, the
MDM2 I440K mutant was able to limit p53 activity in vi-
tro, allowing cells expressing this mutant MDM2 to pro-
liferate. However, cells expressing MDM2 I440K showed
clear accumulation of p53 and an enhanced cellular stress
response, allowing for more rapid activation of p53 signal-
ing in response to genotoxic stress. These results indicat-
ed that under normal tissue culture conditions, the
binding of MDM2 to p53 is sufficient to control p53 func-
tion, but that this regulation may be more sensitive to ac-
tivation in response to stress. To explore the in vivo
consequences of selective loss of MDM2’s E3 activity,
we generated a knock-in mouse model of the murine
MDM2 mutant analogous to the MDM2 I440K human
mutant (MDM2 I438K) and analyzed the effects of this
mutant on the p53-MDM2 regulatory loop during murine
development, under normal physiological conditions, and
in response to DNA damage.
Results
Loss of MDM2 E3 activity is not detrimental to primary
murine cell proliferation
To understand the in vivo consequences of loss of E3 ac-
tivity in MDM2 in mice, we first generated mutations in
mouse Mdm2 at residues analogous to human MDM2
C464, I440, and R479 (C462A, I438K, I438E, and R477P),
which were previously shown to abrogate E3 function.
Transfection of these mutants with p53 into mouse em-
bryo fibroblasts (MEFs) confirmed a similar defect in the
ability to degrade p53 compared with wild-type MDM2
(Supplemental Fig. S1A,B). To take this analysis further,
we focused on the I438K mutant. Surface plasmon reso-
nance (SPR) analysis of MDM2 WT and MDM2 I438K
GST-tagged mouse MDM2 RING domains showed that
the I438K mutant lost the ability to bind UbcH5B-Ub,
while an in vitro autoubiquitination assay confirmed
that the I438K mutant was defective for E3 activity (Sup-
plemental Fig. S1C,D). As expected, MDM2 I438K simi-
larly failed to enhance ubiquitination of p53 compared
with the wild-type MDM2 protein in vitro (Supplemental
Fig. S1E). However, the I438K mutant retained the ability
to interact with both MDM4 (Supplemental Fig. S1F) and
p53 (Supplemental Fig. S1G) similarly to wild-type
MDM2. Taken together, the data confirm similar profiles
of activity for mouse MDM2 I438K as previously de-
scribed for human MDM2 I440K.
To assess the consequences of selective loss ofMDM2’s
ability to interact with E2/ubiquitin on the p53 pathway
in vivo, we generated a conditional knock-in mouse ex-
pressing the I438K mutant using the approach illustrated
in Supplemental Figure S1H. In brief, the targeted allele
(tm1 allele) introduced a second copy of the last two exons
Humpton et al.
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of WTMdm2 (Exons 11 and 12) containing the I438Kmu-
tation (Supplemental Fig. S1H). Subsequent excision of
the Neo cassette was achieved using FLP-FRT recombina-
tion (tm1.1 allele). Cre recombinase-mediated excision of
the wild-type exons 11 and 12 leads to the expression of
endogenous Mdm2 carrying the I438K mutation (tm1.2
allele). Baby mouse kidney cells (BMKs) isolated from
mice carrying the tm1 allele were used for initial valida-
tion of the activity of the I438K allele in vitro. As seen
in the transient MEF system, adenoviral Cre-induced ex-
pression ofMDM2 I438K resulted in robust accumulation
of p53, reflecting the loss of MDM2’s ability to target p53
for degradation (Fig. 1A). In this model, a more modest ac-
cumulation of the MDM2 I438K protein was also detect-
ed, consistent with the previously described auto-
ubiquitination activity of MDM2 (Fang et al. 2000; Honda
and Yasuda 2000). Importantly, induction of MDM2
I438K did not lead to an increase in the expression of
Cdkn1a (p21), a transcriptional target of p53, at either pro-
tein (p21) or mRNA levels (Fig. 1A/B; Supplemental Fig.
S1I). Consistent with previous work, these results show
that the elevated level of p53 seen in MDM2 I438K-ex-
pressing BMK cells was not transcriptionally active.
To interrogate the p53 response in cells expressing
MDM2 I438K, we treated BMK cells with Nutlin-3a (Nut-
lin), a small molecule that inhibits the MDM2-p53 inter-
action to activate p53 (Vassilev et al. 2004). While
treatment of wild-type MDM2-expressing cells with Nut-
lin for 3 h led to the stabilization of p53, as expected, treat-
ment for this short time did not translate into increased
p21 protein levels. In contrast, at 3 h after Nutlin treat-
ment, MDM2 I438K-expressing BMK cells already
showed a significant increase in p21 expression (Fig. 1A),
consistent with the enhanced sensitivity of these cells
to p53 activating signals previously reported in the human
system (Nomura et al. 2017). Direct analysis of mRNA
confirmed the ability of MDM2 I438K to restrain the abil-
ity of p53 to activate expression of the p53 target genes
Cdkn1a (p21) and Mdm2 in otherwise unstressed BMK
cells (Fig. 1B,C). However, these cells showed a more ro-
bust activation of a p53 transcriptional response within
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Figure 1. Mouse Mdm2I438K restrains basal p53 but allows for an enhanced p53 response in vitro. (A) Western blot analysis after 3-h
treatment with control (DMSO) or Nutlin (4 μM) of Mdm2I438K/I438K (I438K) and Mdm2WT/WT (WT) BMK cells first treated for 24 h
with Adeno-empty (EV) or Adeno-Cre and left for 5 d prior to experiment. All proteins detected on one blot with ACTIN used as loading
control. ProteinMW ladder (in kilodaltons) as depicted. Representative blot from three independent experiments. (B,C ) RT-qPCR analysis
of expression of p53 target genesCdkn1a (p21) (B) andMdm2 (C ) after 1-h treatmentwithDMSO (UT) or 4 μMNutlin (NUT) in BMK cells
as inA.N=3/6WT/I438K-independent samples. Data presented asmean±SEM and analyzed using two-way ANOVAwith Holm-Sidak’s
multiple comparisons test and multiplicity-adjusted P-values. (D,E) Cell cycle distribution of Mdm2I438K/I438K (I438K) and Mdm2WT/WT
(WT) BMKcells first treated for 24 hwithAdeno-Cre, left for 5 d, and thenwithDMSOcontrol (UT) orwith 4 μMNutlin (NUT) (D) or 1 μM
doxorubicin (DOX) (E) for 8 h prior to analysis. N=3 UT, N=4 NUT/DOX WT, N=2 NUT/DOX I438K-independent samples. Same UT
data shown in both D and E. Data presented as mean ± SEM and analyzed using two-way ANOVA with Holm-Sidak’s multiple
comparisons test and multiplicity-adjusted P-values. (F ) Western blot analysis in RosaCreER; Mdm2I438K/I438K (I438K) and RosaCreER;
Mdm2WT/WT (WT)MEFs for 5 d after treatment with 1 μM4-OHT at day 0. All proteins detected on one blot with ACTIN used as loading
control. Protein MW ladder (in kilodaltons) as depicted. Representative blot from three independent experiments. (G,H) Relative cell
growth of MEFs from F treated with DMSO (G) or H2O (H) vehicle control or with 4 μM Nutlin (NUT) (G) or 1 μM doxorubicin (DOX)
(H).N =3 independent replicates/condition. Data presented asmean ±SEMand analyzed using two-wayANOVAwithHolm-Sidak’smul-
tiple comparisons test and multiplicity-adjusted P-values.
In vivo requirements for MDM2 E3 activity
GENES & DEVELOPMENT 119
 Cold Spring Harbor Laboratory Press on October 27, 2021 - Published by genesdev.cshlp.orgDownloaded from 
wild-type p53 (Fig. 1B,C). A similarly rapid response to the
DNA-damaging agent doxorubicin was seen in the activa-
tion of Cdkn1a (p21) and Bax expression (Supplemental
Fig. S1I,J). Extending the duration of treatment confirmed
that the wild-type p53-expressing cells also responded to
these doses of Nutlin and doxorubicin by activating ex-
pression of p21 and Mdm2 (Supplemental Fig. S1K–N).
Compromised induction of Cdkn1a (p21) and Mdm2 in
p53-null cells demonstrated the p53 dependence of these
responses (Supplemental Fig. S1K–N). Consistent with
the lack of transcriptional response, the expression of
MDM2 I438K did not impact cell cycle distribution of
BMK cells under normal growth conditions (Fig. 1D,E).
However, in response to p53 activation by Nutlin or dox-
orubicin, the rapidly increased p21 expression evident in
MDM2 I438K-expressing cells was accompanied by a
clear increase of cells in G1 and a reduction in cells in S-
phase of the cell cycle. This response was seen within 8
h of treatment, at a time point where no changes in the
cell cycle were yet seen in MDM2 WT cells (Fig. 1D,E).
Finally, we derived MEFs from mice carrying both the
inducible Mdm2I438K tm1.1 allele (Mdm2I438K/I438K) and
a tamoxifen-inducible Rosa26-CreERT2 (Rosa-CreER) al-
lele (Hameyer et al. 2007) and assessed their response to
p53 induction. As in BMK cells, the induction of mutant
MDM2 in response to Cre recombinase activation by 4-
hydroxytamoxifen (4-OHT) resulted in an accumulation
of p53 protein (Fig. 1F). Under unstressed conditions,
MEFs expressing MDM2 I438K grew similarly to MDM2
wild-type cells, yet they showed an accelerated prolifera-
tive arrest in response to Nutlin or doxorubicin treatment
(Fig. 1G,H). Combined with our BMK data, these findings
confirm that the mouseMDM2 I438Kmutant fails to tar-
get p53 for degradation, but is able to restrain transcrip-
tion from elevated p53 in unstressed situations.
However, cells expressing this mutant show a rapid and
robust p53-mediated response to stress in vitro.
Loss of MDM2 E3 activity leads to embryonic lethality
but is tolerated in adult mice
Having established that the expression of MDM2 I438K
was not detrimental to the proliferation of cells under un-
stressed conditions in vitro, we looked at the consequenc-
es of expression of this MDM2 mutant during mouse
development. In initial experiments, we crossedmice car-
rying the inducible Mdm2I438K mutant allele (tm1) with
mice carrying a ubiquitously expressed Deleter-Cre con-
struct (Schwenk et al. 1995), inducing constitutive hetero-
zygous expression of Mdm2I438K (Mdm2I438K/WT) in
ensuing offspring. ResultingMdm2I438K/WT mice were in-
tercrossed to generate Mdm2I438K/I438K homozygous
mice. None of the pups born from this crosswere homozy-
gous for the mutant allele, suggesting that expression of
MDM2 I438K is embryonically lethal (Fig. 2A). A closer
examination of embryos from this mating strategy
showed that Mdm2I438K/I438K mice survived until E12.5
but were subsequently undetectable by E14.5 (Fig. 2A).
Histology of embryos wild-type or homozygous for
Mdm2I438K at E12.5 did not reveal any clear morphologi-
cal differences (Supplemental Fig. S2A). However, IHC
showed a clear increase in expression of the p53 target
geneCdkn1a (p21), which was accompanied by increased
cleaved caspase 3 (CC3) staining, indicating enhanced ap-
optosis, and decreased expression of the proliferation
marker KI-67 in the I438K homozygous embryos (Fig.
2B; Supplemental Fig. S2A). For comparison, MDM2-
null embryos die through apoptosis around E3.5 (Jones
et al. 1995;Montes de Oca Luna et al. 1995; Chavez-Reyes
et al. 2003), while mice carrying a RING domain-disrupt-
ing MDM2 mutant (MDM2 C462A) die at E7.5 and mice
carrying a RING domain-disrupting MDMX mutant die
at E9.5 (Itahana et al. 2007; Huang et al. 2011). Therefore,
while mice expressing MDM2 I438K survive longer than
other MDM2 E3-deficient mice, the ability of MDM2
I438K to restrain p53 activity is not sufficiently robust
to support full embryonic development.
To confirm that the observed embryonic lethality
in Mdm2I438K/I438K mice was a consequence of uncheck-
ed p53 activity during development, we generated a
compound MDM2 I438K and p53 knockout mouse
(Mdm2I438K/I438K; p53KO/KO) through intercrossing
Mdm2I438K/WT; p53KO/WT mice. Consistent with the re-
ports from other MDM2-null and MDM2 E3-deficient
mice, Mdm2I438K/I438K; p53KO/KO mice were viable
and indistinguishable from littermate control mice
(Mdm2I438K/WT; p53KO/KO) (Supplemental Fig. S2B,C;
Jones et al. 1995; Montes de Oca Luna et al. 1995; Cha-
vez-Reyes et al. 2003; Itahana et al. 2007). Tissues from
Mdm2I438K/I438K; p53KO/KO and Mdm2I438K/WT; p53KO/KO
mice at 5 mo of age exhibited similar organ morphology
and histological analysis revealed that both sets of mice
had developed small tomedium-sized thymic lymphomas
independently of MDM2 status by this time (Supplemen-
tal Fig. S2B), consistent with the normal disease trajectory
of p53KO/KO mice (Donehower et al. 1995).
Given the lethality of Mdm2I438K/I438K constitutive
mice, we sought to examine the consequences of switch-
ing to MDM2 I438K expression in adult mice by using
Rosa-CreER to replace Mdm2 WT exons 11/12 with those
containing the mutant Mdm2I438K allele (tm1), through
tamoxifen-induced Cre-mediated recombination. An ini-
tial induction protocol using the intraperitoneal (IP) injec-
tion of tamoxifen resulted in progressive weight loss in
Mdm2I438K/I438K; Rosa-CreER-positive mice that reached
clinical endpoint (Fig. 2C). At necropsy, these mice had
diarrhea and subsequent histological examination re-
vealed clear damage to the colon and small intestine in
IP tamoxifen-induced Mdm2I438K/I438K; Rosa-CreER-posi-
tive mice (Fig. 2D; Supplemental Fig. S2D). Along with
the sustained weight loss, our observations suggested
gut toxicity arising as a consequence of our induction re-
gime. We hypothesized that this outcome might reflect
an on-target p53 response to intestinal stress caused by
the IP delivery of a bolus of sunflower oil, the vehicle for
tamoxifen in this experiment. To test this idea, we in-
duced Mdm2I438K/I438K; Rosa-CreER-positive mice
through the subcutaneous (SC) delivery of tamoxifen in-
stead, after having first validated thismethod by assessing
recombination using R26tdRFP; Rosa-CreER reporter mice
Humpton et al.
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(Luche et al. 2007). In the R26tdRFP mouse, Cre recombi-
nase activity excises the Lox-STOP-Lox (LSL) cassette
blocking ubiquitous Rosa26-linked RFP expression
(R26LSL-tdRFP), allowing for RFP expression only in tissues
that have undergone successful recombination. As such,
analysis for RFP reveals where Cre recombinase was ac-
tive in each reporter mouse (Luche et al. 2007). In
R26tdRFP; Rosa-CreER mice, we observed equivalent RFP
expression by IHC across all tissues examined between
mice induced by tamoxifen given through IP or SC injec-
tion, confirming equivalent induction efficiency with
the SC induction regime (Supplemental Fig. S2E,F).
Using the SC tamoxifen induction regime, there was no
detectible deleterious effect of the switch to homozygous
MDM2 I438K expression on the weight or activity of
RosaCreER;Mdm2I438K/I438Kmice over the first 10 d follow-
ing tamoxifen treatment (Fig. 2E). By comparison, deletion
of MDM2 in adult Mdm2FL/FL mice using the same SC ta-
moxifen protocol resulted in rapid weight loss by 4 d after
the first tamoxifen injection (Fig. 2E) – results that are in ac-
cordance with previously published data (Ringshausen
et al. 2006; Zhang et al. 2014). The rapid response to
Mdm2 deletion using this Cre induction protocol indicates
efficient recombination of the Mdm2 allele, comparable
with that seen in previous studies. Further analysis of liver
and small intestine from the induced RosaCreER;
Mdm2I438K/I438K mice at 5 and 10 d after induction con-
firmed efficient recombination of the mutant allele (Sup-
plemental Fig. S2G), suggesting a lack of short-term
selection againstMDM2 I438K expression.Histological ex-
amination ofRosaCreER;Mdm2I438K/I438Kmice revealed no
pronouncedchanges in tissue histology after either 5 or 10d
after the switch to MDM2 I438K expression (Fig. 2F,G). In-
deed, theMDM2 I438K-expressing mice remained healthy
for at least 4 mo and were indistinguishable from litter-
mates throughout this timeframe in terms of survival,
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Figure 2. Inducible switch to Mdm2I438K expression is viable in adult mice. (A) Genotypes of 50 pups born to Mdm2I438K/WT X
Mdm2I438K/WT matings (offspring from five mating pairs) and the gestational age and genotypes of embryos obtained from 10 timed mat-
ings of Mdm2I438K/WT X Mdm2I438K/WT mice. Mdm2I438K/I438K mice denoted as “HOM.” Litter data analyzed using a χ2 test as shown.
Brackets denote expected frequencies. (B) Quantification of p21, cleaved caspase 3 (CC3), and KI-67 staining in E12.5 Mdm2WT/WT
(MDM2 WT) and MDM2I438K/I438K (I438K HOM) embryos. N=3 embryos/group derived from three timed matings. Data analyzed using
multiple t-tests with Holm-Sidak’s method to correct for multiple comparisons. (C ) Weights from RosaCreER; Mdm2I438K/I438K (I438K),
Mdm2I438K/I438K (I438K no Cre), andMdm2WT/WT (WT) (two Cre-positive, one negative) mice during IP tamoxifen induction presented as
percent change from preinduction baseline measurement. N= 3 mice per group. Data are presented as mean±SEM. (D) Representative
H&E staining of duodenum and colon of RosaCreER; Mdm2I438K/I438K (I438K) and RosaCreER; Mdm2WT/WT (WT) mice from C. Scale
bar, 20 μm. (E) Weights from RosaCreER; Mdm2I438K/I438K (I438K), RosaCreER; Mdm2WT/WT (WT), and RosaCreER; Mdm2FL/FL (FL/FL)
mice during SC tamoxifen induction protocol presented as percent change from preinduction baseline measurement. N=4 WT/I438K
and N = 1 FL/FL. Data are presented as mean±SEM. (F ) Representative H&E staining of proliferative tissues in uninduced mice and at
5 d after initial dose of SC tamoxifen treatment in RosaCreER; Mdm2I438K/I438K (I438K) and RosaCreER; Mdm2WT/WT (WT) mice. Scale
bar, 20 μm. N=7 WT and N=6 I438K uninduced mice and N= 4 induced mice per group at 5 d after induction. (G) Representative
H&E staining of nonproliferative tissues as in F at 10 d after initial dose of SC tamoxifen induction. Scale bar, 20 μm. N =7 WT and N
=6 I438K uninduced mice and N=6 WT and N =5 I438K induced mice at 10 d per group. (H) Long-term weight measurements from
male RosaCreER; Mdm2I438K/I438K (I438K) and RosaCreER; Mdm2WT/WT (WT) mice after SC tamoxifen induction protocol presented as
percent change from preinduction baseline measurement. N= 4 WT and N =2 I438K (all males). Data presented as mean± range. (I ) Rep-
resentativeH&E staining from indicated tissues of agedRosaCreER;Mdm2I438K/I438K (I438K) andRosaCreER;Mdm2WT/WT (WT)mice from
H. N= 4 WT and N=2 I438K mice. Scale bar, 20 μm.
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weight gain, and activity (Fig. 2H,I). Taken together, the
data suggest that MDM2 I438K is capable of limiting p53
activity in adult mice in vivo.
Organ-specific changes in p53 activity following MDM2
I438K induction
Immunohistochemical analysis of RosaCreER;
Mdm2I438K/I438K mice at 5 and 10 d after SC tamoxifen in-
duction showed a clear stabilization of p53 across all organs
tested, compared with mice expressing wild-type MDM2
(RosaCreER; Mdm2WT/WT) (Fig. 3A–D). However, the time
to reach peak stabilization of p53 varied across tissues,
with high-levels of p53 evident by 5 d after the first tamox-
ifen injection in proliferative tissues—including the small
intestine, colon, and spleen—and a more gradual accumu-
lation over 10 d in the pancreas and liver (Fig. 3A–D).
To assess the ability of MDM2 I438K to regulate p53
activity, we examined p21 protein expression by IHC
in various organs of these mice at 5 and 10 d after induc-
tion. In contrast to cells in culture, where p21 expression
remained low despite p53 accumulation, each tissue
showed an induction of p21 protein that coincided
with the stabilization of p53 (Fig. 3E–H). Specifically,
p21 accumulation was highest in the spleen, duodenum,
and colon at 5 d after induction, with evidence for a re-
duction (spleen) or a return to baseline (duodenum and
colon) expression by 10 d, despite the maintenance of
high p53 levels at this time point (Fig. 3B). In the liver
and pancreas, an increase in p21 levels was delayed,
with maximal induction seen at 10 d after induction, co-
inciding with the delayed accumulation of p53 (Fig. 3H).
Two important responses to p53 activation are prolifera-
tive arrest and induction of cell death. While p21 is a key
mediator of p53-induced cell cycle arrest, p53 activates
the expression several apoptotic proteins, including
BAX. Interestingly, BAX expression following induction
of MDM2 I438K generally followed the pattern of p21 ex-
pression (Supplemental Fig. S3A,B), with a transient in-

































































































































Figure 3. Persistent p21 expression corresponds with organ dysfunction after switch toMdm2I438K expression in vivo. (A–D) Represen-
tative IHC staining and quantification of p53 intensity in the indicated proliferative (A,B) and nonproliferative (C,D) tissues ofRosaCreER:
Mdm2I438K/I438K (I438K) and RosaCreER; Mdm2WT/WT (WT) animals at indicated time points following initial dose of subcutaneous (SC)
tamoxifen induction. Scale bar, 20 μm.N= 7WTandN =6 I438Kuninducedmice (UT).N=4mice per group at 5 d after induction andN =6
WT and N= 5 I438K mice at 10 d after induction. Data are presented as mean ± SEM and analyzed using two-way ANOVA with Holm-
Sidak’s multiple comparisons test and multiplicity-adjusted P-values examining effects of genotype over time within each tissue.
(E–H) Representative IHC staining in the duodenum (E) and pancreas (F ) and quantification of p21 intensity in the indicated proliferative
(G) and nonproliferative (H) tissues of the same mice as A–D at indicated time points following initial dose of tamoxifen induction (SC).
The p21 data inH additionally include quantification of p21 in the liver and pancreas of mice in the longer term (2 and 4 mo) after induc-
tion (LT).N=3WT andN=2 I438K LTmice. Scale bar, 20 μm. Data presented as mean ± SEM and analyzed using two-way ANOVAwith
Holm-Sidak’s multiple comparisons test and multiplicity-adjusted P-values examining effects of genotype over time within each tissue.
(I ) Determination of plasma lipase activity (milliunits per milliliter) fromRosaCreER;Mdm2I438K/I438K (M2) andRosaCreER;Mdm2WT/WT
(WT) animals 10 d after initial dose of SC tamoxifen induction (10 d) and in the longer term (2 and 4 mo) after induction (LT).N=3/group
exceptN =2 LTMdm2I438K/I438K mice. Mean±SEM and data points shown. Data for 10-d mice are also shown in Figure 5K (“no IR”) and
data from LTmice are also shown in Figure 4K. Data analyzed using two-way ANOVAwith Holm-Sidak’s multiple comparisons test and
multiplicity-adjusted P-values.
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the proliferative organs (spleen, duodenum, and colon)
and a persistence of expression at 10 d in liver and pan-
creas. Further analysis of duodenum and liver confirmed
the pattern of Cdkn1a (p21) and Bax expression at the
mRNA level (Supplemental Fig. S3C,D), consistent
with this being a transcriptional response to p53. Fur-
thermore, the expression of Noxa (also known Pmaip1)
and Puma (also known as Bbc3), additional apoptotic
p53 target genes, generally confirmed this pattern of ex-
pression (Supplemental Fig. 3SC,D). The exception was
Puma mRNA expression in the liver, which increased
at 5 d, but then declined to baseline by 10 d after induc-
tion (Supplemental Fig. S3D).
Taken together, these observations suggest that al-
though the MDM2 I438K mutant is able to restrain p53
levels sufficiently to prevent weight loss or lethality, the
mutant does not completely limit the transcriptional ac-
tivity of stabilized p53 in all murine tissues. To determine
the outcome to these responses, we tested proliferation
(measured by Ki-67 staining) and apoptosis (measured by
CC3 staining). Inmost tissues, despite the induction of ex-
pression of p21 and several apoptotic proteins, there was
no evidence of significant proliferative arrest or apoptosis
following induction of MDM2 I438K (Supplemental Fig.
S3E–G), although a transient reduction in proliferation
was seen in the spleen at 5 d, which recovered by 10
d. Overall, these data suggest that the increased p53 activ-
ity inRosaCreER;Mdm2I438K/I438Kmicewas not sufficient
to cause undue arrest or cell death, consistent with the
lack of toxicity in mice following induction.
Despite this lack of evidence for either proliferative ar-
rest or apoptosis, our data revealed a persistence of the
p53 response in liver and pancreas at 10 d after induction
and additional analysis of p21 expression in the longer
term following induction showed a recovery to
baseline in the liver after several months but persistence
of enhanced expression in the pancreas (Fig. 3H). To ex-
amine more closely whether there were any consequenc-
es of induction of the p53 response in RosaCreER;
Mdm2I438K/I438K mice, we analyzed liver and pancreas
function in both 10 d after induction mice and longer-
term age-induced mice. Liver function was assessed by
measuring plasma activity of ALT (alanine aminotrans-
ferase) and AST (aspartate aminotransferase), two liver
enzymes that are elevated in the circulation following
liver damage. Modestly increased levels of both ALT
and AST activity were seen in the plasma of 10-d induced
RosaCreER; Mdm2I438K/I438K mice compared with control
mice (Supplemental Fig. S3H,I), although these levels
normalized over the longer term, suggesting that any liv-
er dysfunction was mild and transient and consistent
with the recovery of restrained p21 expression by this
time. To assess pancreas function, we examined the lev-
els of plasma lipase, a pancreatic enzyme that is increased
in the blood following pancreatic damage. Interestingly,
plasma lipase activity increased with age in the wild
type mice (Fig. 3I). However, we also observed signifi-
cantly increased levels of plasma lipase in 10-d induced
RosaCreER; Mdm2I438K/I438K mice that persisted in the
longer term, suggesting an ongoing but stable increase
in pancreatic dysfunction resulting from persistent ex-
pression of the MDM2 I438K mutant (Fig. 3I).
Rapid induction of the p53 stress response in MDM2
I438K-expressing mice
In our in vitro experiments, Mdm2I438K-expressing cells
proliferated normally but were significantly more sensi-
tive to p53 activating signals such asNutlin and doxorubi-
cin (Fig. 1; Supplemental Fig. S1). To determine whether
the same enhanced response to stress could be detected
in vivo, we exposed pairs of 10-d postinduction MDM2
WT and RosaCreER; Mdm2I438K/I438K mice to nonlethal
6 Gy total body γ-irradiation (TBI) and followed the p53 re-
sponse over a short 8-h time course. Consistent with pre-
vious reports (Pant et al. 2013; Tollini et al. 2014), these
studies revealed stabilization of p53 in the radiosensitive
spleen, duodenum, and colon after TBI in MDM2 WT
mice (Supplemental Fig. S4A) with a corresponding in-
crease in p21 protein expression by 8 h after TBI (Fig.
4A,B). In RosaCreER; Mdm2I438K/I438K mice, p53 levels
were higher before TBI and showed a further rapid stabili-
zation by 2 h (Supplemental Fig. S4A), correlating with a
more robust induction of p21 in these tissues compared
with MDM2WT mice (Fig. 4A,B). Interestingly, evidence
for a rapid recovery from this response was seen in the
spleen where p53 and p21 levels declined by 8 h after
TBI. Levels of BAX proteinwere similarly induced to high-
er levels in I438K spleen, duodenumand colon than inWT
tissue (Fig. 4C), a response that was more pronounced in
the spleen and corresponded with increased cell death in
spleen, but not the duodenum or colon at these early
time points (Fig. 4D). Analysis of mRNA expression in
duodenum confirmed increased Cdkn1a (p21), Bax,
Noxa, and Puma expression in response to TBI in
MDM2 WT mice with a substantial enhancement of
this response for all p53 target genes in the RosaCreER;
Mdm2I438K/I438K mice (Supplemental Fig. S4B). However,
despite the increase in apoptotic gene expression, only
the spleen showed transient elevation in apoptosis at 2 h
after TBI (Fig. 4D).
In contrast to radiosensitive tissues, no clear stabiliza-
tion of p53 was detected in radioresistant tissues (pancre-
as and liver) in response to 6 Gy TBI inWTmice, although
in I438K mice both tissues sustained higher levels of p53
(Supplemental Fig. S4C). Similarly, p21 and BAX levels
were substantially higher in I438K liver and pancreas
both before and after TBI (Fig. 4E–G). Transcription of
Cdkn1a (p21), Bax andNoxawas also significantly higher
in the liver of TBI I438K mice compared with wild-type
mice (Supplemental Fig. S4D), although liver Puma tran-
scription was not increased in either wild-type or I438K
mice in response to IR, supporting some tissue specificity
to the p53 targets that are engaged in response to stress. In-
terestingly, while no cell death was apparent in the liver,
the pancreas showed a rapid and dramatic increase in CC3
staining withinMDM2 I438K-expressing acinar cells (Fig.
4H,I).
In vivo requirements for MDM2 E3 activity
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Figure 4. Mdm2I438K mice respond more robustly to 6 Gy IR, leading to acute lethality in the pancreas. (A) Representative IHC staining
for p21 in the indicated proliferative tissues at the indicated time points (in hours) after 6 Gy TBI administered 10 d after SC tamoxifen
induction inRosaCreER;Mdm2I438K/I438K (I438K) andRosaCreER;Mdm2WT/WT (WT)mice.N= 6WTandN=5 I438K control inducedmice
(no IR) and N=4 WT and N =3 I438K mice per irradiation time point. Scale bar, 20 μm. (B–D) Quantification of p21 (B), BAX (C ), and
cleaved caspase 3 (CC3; D) staining in the indicated proliferative tissues of the mice from A. Data are presented as mean±SEM and an-
alyzed using two-way ANOVAwith Holm-Sidak’s multiple comparisons test and multiplicity-adjusted P-values examining effects of ge-
notype over time within each tissue. (E) Representative IHC staining for p21 in the liver and pancreas at the indicated time points (in
hours) after 6 Gy TBI administered 10 d after SC tamoxifen induction in RosaCreER; Mdm2I438K/I438K (I438K) and RosaCreER;
Mdm2WT/WT (WT) mice. N=6 WT and N=5 I438K control induced mice (no IR) and N=4 WT and N =3 I438K mice per irradiation
time point. Scale bar, 20 μm. (F,G) Quantification of p21 (F ) and BAX (G) staining in the indicated nonproliferative tissues of the mice
depicted in A. Data are presented as mean±SEM and analyzed using two-way ANOVA with Holm-Sidak’s multiple comparisons test
and multiplicity-adjusted P-values examining effects of genotype over time within each tissue. (H,I ) Representative IHC staining and
quantification of cleaved Caspase 3 (CC3) in the liver and pancreas of mice from E. Data presented as mean±SEM and analyzed using
two-way ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-adjusted P-values examining effects of genotype over
time within each tissue. (J) Survival curve comparing adult RosaCreER; Mdm2I438K/I438K (I438K) and RosaCreER; Mdm2WT/WT (WT)
mice for 50 d after 6 Gy TBI treatment.N=6mice/group.N= 2mice/group reached clinical endpoint prior to 50 d. Survival analyzed using
Log-rank (Mantel-Cox) test. (ns) Not significant. (K ) Representative H&E staining of the indicated tissues in RosaCreER;Mdm2I438K/I438K
(I438K) andRosaCreER;Mdm2WT/WT (WT)mice at 50 d after 6 Gy TBI.N=4mice/group. Scale bar, 20 μm. (L–N) Determination of plasma
ALT (L), AST (M ), and lipase activity (N) (all inmilliunits permilliliter) inRosaCreER;Mdm2I438K/I438K (M2) andRosaCreER;Mdm2WT/WT
(WT)mice in the longer term (2 and 4mo) after induction (LT) andmice at 50 d after 6GyTBI (6Gy).N=4mice/group in 50-d cohorts,N =3
LTWTmice, andN=2 LTMdm2I438K/I438Kmice.Mean±SEM and data points shown. Data analyzed using two-wayANOVAwith Holm-
Sidak’s multiple comparisons test and multiplicity-adjusted P-values. Data from aged mice are also presented in Supplemental Figure S3,
H and I (ALT/AST), and Figure 3I (lipase).
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The increase in the strength and duration of the activa-
tion of the p53 response in RosaCreER; Mdm2I438K/I438K
mice following acute nonlethal TBI, and especially the un-
expectedly potent engagement of p53-induced cell death
in the pancreas, raised the possibility of more severe
long-term consequences of exposure to p53 activating sig-
nals in RosaCreER; Mdm2I438K/I438K mice. Previous stud-
ies have shown that while 6 Gy TBI can be tolerated by
Mdm2 WT mice without impact on medium-term sur-
vival, it can be lethal in a mouse model where the
MDM2-p53 feedback loop is removed (MDM2 P2 mice)
or in mice with an extreme C-terminal Mdm2 mutation
that disrupts MDM2 E3 activity (Pant et al. 2013; Tollini
et al. 2014). However, we found no decreased survival in
RosaCreER; Mdm2I438K/I438K mice exposed to 6 Gy TBI
compared with Mdm2 WT mice (Fig. 4J). At 50 d after 6
Gy TBI, RosaCreER; Mdm2I438K/I438K and RosaCreER;
Mdm2 WT mice showed similar tissue histology (Fig.
4K), although we did observe slightly elevated plasma
ALT and AST activity—suggesting some liver dysfunc-
tion arising from 6 Gy TBI (Fig. 4L,M). Interestingly, the
acute pancreatic acinar attrition observed in RosaCreER;
Mdm2I438K/I438K mice after 6 Gy TBI was not accompa-
nied by a further loss of pancreas function–seen as amain-
tenance but not increase in plasma lipase activity (Fig.
4N). These observations suggest some level of recovery
and regeneration of the exocrine pancreas (Zhou andMel-
ton 2018).
In humans, targeted radiation treatment for cancer pa-
tients can result in exposure of both tumor-adjacent nor-
mal and more distant peripheral tissues to a lethal
irradiation dose (Quast 2006). Given thewell-documented
on-target toxicities limiting the therapeutic efficacy of
“Nutlin-like” compounds,wewere interested inexploring
the effect of putative MDM2 E3 inhibitors on normal tis-
sue in response to higher radiation exposure. We chose 8
Gy TBI, a dose on the low end of the lethal range for
mice, with an expected LD50 time (time until lethal
dose for 50%ofmice) beyond1wk (Booth et al. 2012), com-
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Figure 5. The acute response to lethal 8 Gy IR is exacerbated in both sensitive and nonradiosensitive tissues in Mdm2I438K mice. (A,B)
Representative IHC staining and quantification of p53 in the indicated tissues at 3 d after 8 Gy TBI treatment administered 10 d after be-
ginning of SC tamoxifen induction in RosaCreER;Mdm2I438K/I438K (M2) andRosaCreER;Mdm2WT/WT (WT) mice.N=4 mice/group. Scale
bar, 20 μm. (Duo) Duodenum, (Panc) pancreas. Data analyzed using multiple t-tests with Holm-Sidak’s method to correct for multiple
comparisons. (C,D) Representative IHC staining and quantification of p21 as inA andB.N=4mice/group. (E,F ) Representative IHC stain-
ing and quantification of cleaved caspase 3 (CC3) as inA and B.N=4mice/group. (G,H) Representative IHC staining and quantification of
phospho-HistoneH2A.X (Ser139) (gH2AX) in the liver and pancreas at 3 d after 8GyTBI treatment administered 10 d after beginning of SC
tamoxifen induction in RosaCreER; Mdm2I438K/I438K (M2) and RosaCreER; Mdm2WT/WT (WT) mice. N=4 mice/group. Scale bar, 20 μm.
Data analyzed using multiple t-tests with Holm-Sidak’s method to correct for multiple comparisons. (I,J) Representative IHC staining
and quantification of malondialdehyde (MDA) as in G andH. N=4 mice/group. Scale bar, 20 μm. Data analyzed using two-way ANOVA
withHolm-Sidak’smultiple comparisons test andmultiplicity-adjusted P-values. (K ) Comparison of plasma lipase activity (milliunits per
milliliter) inRosaCreER;Mdm2I438K/I438K (M2) andRosaCreER;Mdm2WT/WT (WT)mice at 10 d after the start of induction (no IR) and at 3 d
after 8 Gy TBI treatment administered 10 d after beginning of tamoxifen induction.N =3mice/group. Data from “no IR”mice also shown
in Figure 3I (“young induced”mice). Data analyzed by two-way ANOVAwith Holm-Sidak’s multiple comparisons test and multiplicity-
adjusted P-values. (L,M ) Representative IHC staining and quantification of F4/80 in the pancreas as inG andH. N=4 WTmice andN=3
M2mice. Scale bar, 20 μm.Data analyzed using two-wayANOVAwithHolm-Sidak’smultiple comparisons test andmultiplicity-adjusted
P-values.
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after 8 Gy TBI, mice were similarly active in each cohort
and did not yet exhibit clinical signs of radiation sickness.
Histology of the radiosensitive spleen, duodenum, and co-
lon was similar in RosaCreER; Mdm2I438K/I438K and
RosaCreER; Mdm2 WT mice (Supplemental Fig. S5A), al-
though as expected, the RosaCreER; Mdm2I438K/I438K
mice exhibited increased levels of both p53 and p21 stain-
ing (Fig. 5A–D). However, in contrast to our data from
short-term 6 Gy TBI treatment, the enhanced p53 signal-
ing that we observed in RosaCreER; Mdm2I438K/I438K
mice after 8 Gy TBI treatment correlated with increased
CC3 staining across all radiosensitive tissues (Fig. 5E,F).
As in radiosensitive organs, we noted robust p53 accu-
mulation and p21 expression in both the liver and the pan-
creas of RosaCreER; Mdm2I438K/I438K mice (Fig. 5A–D),
although increased CC3 staining was only evident in the
pancreas and not in the liver (Fig. 5E,F). Both the liver
and pancreas showed evidence of deteriorated tissue ar-
chitecture and unresolved DNA damage, identified by
phospho-H2AX-positive foci (gH2AX) (Fig. 5G,H), and in-
creased cellular ROS (Fig. 5I,J; Supplemental Fig. S5B).
However, liver function in RosaCreER; Mdm2I438K/I438K
mice, measured by plasma ALT and AST activity, was
not further compromised by 8 Gy TBI treatment at this
time point (Supplemental Fig. S5C,D). In contrast, pancre-
as function, as judged by plasma lipase activity, showed
further deterioration following 8 Gy TBI (Fig. 5K). Further
evidence for increased pancreas damage was provided by
the identification of greater macrophage content, as
judged by F4/80 staining, in the pancreata of I438K mice
(Fig. 5L,M), reminiscent of the increasedmacrophage infil-
tration evident during pancreatitis (Habtezion 2015; Xue
et al. 2015).
Discussion
We have described the in vivo characterization of an E3
ubiquitin ligase-deficient MDM2 mutant, MDM2 I438K,
which lacks the ability to interact with E2/ubiquitin but
maintains an otherwise functional MDM2 RING finger
domain. Although the MDM2 I438K mutant has lost
the E3-dependent features of MDM2 regulation of p53, it
retains the ability to control p53 transcriptional activity.
Several MDM2 mutant mice have been reported, includ-
ing those altered in the RING domain (C462A) and in
the C-terminal tail (Y487A) (Itahana et al. 2007; Tollini
et al. 2014). Unlike the I438K mutant described here,
C462A disrupts the structure of the RING and results in
more general loss of the ability to control p53. The C-ter-
minal tail Y487A mutant, by comparison, compromises
MDM2 homodimer binding to E2-Ub, but can be rescued
by heterodimerizationwithMDMX.A clear difference be-
tween the efficiency of Y487A and I438K in controlling
p53 is seen by the embryonic lethality associated with
the expression of the latter, but not the former. Our data
indicate that the E3 ligase activity of MDM2 is necessary
for embryogenesis.
In contrast, induction of I438K expression in the adult
mouse was not lethal and these mice showed no overt pa-
thologies compared with wild-type mice over the course
of several months. As seen in vitro, p53 accumulated in
the tissues of mice expressing MDM2 I438K, consistent
with the loss of E3 activity. However, unlike the in vitro
models, this accumulation of p53 provoked the induction
of a p53 response, as measured by an increase in p21 ex-
pression. This activation of p53 was transient in radiosen-
sitive tissue and was only seen to persist in the pancreas.
There appear to be tissue-dependent differences in the re-
sponse to loss of MDM2 E3 activity and the ability to re-
gain homeostasis of the control of p53. These findings
suggest the existence of cell-specific factors that either
limit or promote MDM2 I438K efficacy in controlling
p53 in vivo that are not recapitulated in in vitro cell cul-
ture systems.
Importantly, while the partial control of p53 activity
shown by MDM2 I438K in vivo is sufficient to allow for
normal growth, these mice displayed an enhanced p53 re-
sponse to DNA damage-inducing TBI. Under nonlethal
TBI, increased p53 activity—as indicated by increased ex-
pression of p21—was detected in radiosensitive tissues,
but this did not lead to increased cell death or decreased
survival. Intriguingly, the MDM2 tail region mutant
Y487A expressing mice were highly sensitive to an even
lower dose of TBI (5Gy) and showed 100%mortalitywith-
in 20 d of treatment (Tollini et al. 2014), accompanied by
haematopoietic failure and apoptosis in the spleen. Fur-
thermore, treatment of RosaCreER; Mdm2I438K/I438K
mice with a lethal dose of TBI did not reveal an overt in-
crease in toxicity, although again evidence of enhanced
stabilization and activation of p53 was seen in various
organs.
An intriguing exception to the general tolerability of
MDM2 I438K expression was the pancreas, where expres-
sion ofMDM2 I438K sensitized acinar cells to p53 apopto-
tic signaling. Even at baseline, the pancreata in
RosaCreER; Mdm2I438K/I438K mice exhibited features of
chronic pancreatic dysfunction as judged by elevated plas-
ma lipase. Beyond that, a mild applied stress such as 6 Gy
TBI—irradiation that caused no discernible changes to
MDM2 WT pancreata—was sufficient to cause rapid
and widespread acinar attrition in RosaCreER;
Mdm2I438K/I438K mice. Perhaps due to the impressive re-
generative capacity of the exocrine pancreas, both the
baseline pancreatic stress and the acute 6 Gy TBI-induced
acinar cell death appeared ultimately tolerable and did
not compromise the viability of aging RosaCreER;
Mdm2I438K/I438K mice or mice in the medium term after
6 Gy TBI.
While we show persistence of the recombined MDM2
allele over the short term,we cannot exclude the selection
of nonrecombined wild-type MDM2 expressing cells in
the long-term agedmice. However, themaintenance of el-
evated p21 in the pancreas suggests the retention of some
level of p53 response consistent with MDM2 I438K ex-
pression. Despite themaintenance ofmurine viability, ev-
idence of persistent pancreas damage was observed.
Furthermore, treatment of RosaCreER; Mdm2I438K/I438K
mice with lethal 8 Gy TBI caused even greater pancreatic
damage, including high levels of unresolved DNA
Humpton et al.
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damage, increased cell death, increased cellular ROS,
macrophage infiltration and further compromised pancre-
atic function. Although these features were not universal-
ly translated to the liver, a second traditionally
nonradiosensitive organ, even here the RosaCreER;
Mdm2I438K/I438K mice exhibited elevated DNA damage
and higher levels of ROS after 8 Gy TBI. These findings
suggest a mixture of tissue-specific and generalizable fea-
tures of MDM2 I438K function that can exacerbate the
p53 response to genotoxic damage.
Taken together, our findings suggest that the E3-defi-
cient MDM2 I438K mutant provides enough control
over elevated p53 levels to allow for homeostasis in adult
mice. Expression of this mutant significantly enhanced
the p53 response in these animals, although this was not
associated with decreased survival in the face of TBI.
More broadly, our results examining the MDM2 I438K
mutant can be viewed as a genetic approximation of the
potential efficacy and utility of future small molecule in-
hibitors specifically targeting MDM2 E3 activity rather
than theMDM2-p53 interaction and act as a proof of prin-
ciple for this approach. In this light, our findings suggest
that such small molecule inhibitors would not show tox-
icity inmany normal tissues andmay bemore likely to ac-
tivate an on-target p53 response in stressed preneoplastic
tissues and tumors.More specifically, an E3 inhibitormay
have wide-ranging and tissue-specific therapeutic win-
dows based on the underlying sensitization of each nor-
mal tissue to p53-mediated cell death from genotoxic
combination therapies. Based on our evidence, liver can-
cers that retain wild-type p53, for example, may be more
likely to usefully respond to MDM2 E3 inhibition than
pancreatic cancers, where the sensitivity to on-target tox-
icity in acinar cells from genotoxic combination therapy
may be high.
Materials and methods
Generation of Mdm2I438K knock-in mice
Aconditional pointmutant allele of theMdm2 gene (Ensembl ID:
ENSMUSG00000020184 inGenomeAssemblyGRCm38.p6) was
generated by gene targeting. This allele replaces exons 11 and
12 (ENSMUSE00001296149 & ENSMUSE00000665547) of the
mouse Mdm2 gene transcript (Ensembl transcript ID: Mdm2-
201; ENSMUST00000020408.15) with an alternate version of
exons 11 and 12 encoding the I438K point mutation upon Cre re-
combination. This changes the ATC codon at positions 418–420
ofMdm2 exon12 to AAG, replacing the isoleucine at position 438
with lysine.
An F3-Neomycin-R cassette was inserted into the Mdm2 tar-
geting vector by cotransfection of EL250 E. coli (Liu et al. 2003).
These E.coli can express Flp recombinase under arabinose induc-
tion. The DNA fragment flanked by the homology arms was ex-
cised and recombineered (Liu et al. 2003) into a pool of mouse
genomic DNA BAC clones (Source Biosciences) carrying the
mouseMdm2 gene in EL350 E.coli (Adams et al. 2005). A retriev-
al plasmid was generated by the PCR amplification of NotI-AscI
linearized pFlexDTA (a modified version of pFlexible; [van der
Weyden et al. 2005]). The modified sequences were retrieved
from BAC clones in EL250 E.coli by recombineering.
The targetingvectorwas sequenceverified prior to transfection.
Itwas then linearized byAscI digestion andused to transfectHM1
mESCs by electroporation (Magin et al. 1992). Cells were selected
under neomycin (300 µg/mL) and surviving colonies were picked
and screened for targeting by long range PCR (using the Roche Ex-
pand long template PCR system) fromwithin the neomycin-resis-
tance cassette to sequences beyond the ends of the homology
arms. Oligo sequences used to screen cells to ensure appropriate
targeting of the Mdm2 gene were GTGGATTGATTTAGGAAA
CAAGATG and CAAGTTAACAACAACAATTGCATTC for
the 5′ side and GCATTGTCTGAGTAGGTGTCATTC and AC
GCAACATTAATACAAAGCTATCC for the 3′ side.
Following identification of correctly targeted clones, mouse
lines were derived by injection of ES cells into C57BL/6J blasto-
cysts according to standard protocols (Nagy et al. 2003). After
breeding of chimeras, germline offspring were identified by coat
color and the presence of the modified allele was confirmed
with the primers described above. The point mutation and re-
combination siteswere sequence verified in themice.Mice carry-
ing the tm1.1 allele were generated by crossing mice harboring
the tm1 allele with a mouse line expressing Flpe (Tg(ACTFLPe)
9205Dym) to delete the selectable marker by recombination at
the FRT sites (Rodríguez et al. 2000). Deletion of the selectable
marker was confirmed by PCR across the remaining F3 site.
Mice
Rosa-CreER [Gt(ROSA)26Sortm2(cre/ERT2)Brn], Deleter-Cre
[Tg(CMV-cre)1Cgn], RFP reporter [Gt(ROSA)26Sortm1Hjf], p53KO/KO
(Trp53tm1Brd), Mdm2FL/FL (Mdm2tm2.1Glo), and Flippase recombi-
nase [Tg(ACTFLPe)9205Dym] mice were described previously (Done-
hower et al. 1992; Schwenk et al. 1995; Rodríguez et al. 2000;
Grier et al. 2002; Hameyer et al. 2007; Luche et al. 2007). The in-
duction time-course, 6 Gy TBI short time-course, and medium-
term 6 Gy TBI 50-d mice were a mix of male and female mice.
Longer-term aging mice were all male. The acute 3-d 8 Gy TBI
treated mice were all female. Mice within each experiment
were age and littermate matched, and all induced at the same
time to the extent this was possible. Mice were treated with ta-
moxifen prior to 6 mo of age. Downstream analyses were per-
formed on a random order of samples blinded to the genotype
and treatment regime until the summation of results.
Procedures involving mice were performed under Home Office
licence numbers 70/8645 and 60/4293. Experiments were con-
ducted in accordance with the Animals (Scientific Procedures)
Act 1986 and the EUDirective 2010 and sanctioned by Local Eth-
ical Review Process (University of Glasgow). Mice were housed
on a 12-h light/12-h dark cycle and provided with normal chow
diet and water ad libitum. All experimental cohort mice were
genotyped by Transnetyx. Founding mice, BMK cells, and MEF
cell lines were genotyped by hand using the genotyping PCR pro-
tocols outlined below.
Tamoxifen (Sigma T5648) was administered to mice >20 g via
intraperitoneal injection a total of four times (3 mg of tamoxifen
on day 1, followed by 2 mg of tamoxifen on days 2, 3, and 4) or by
subcutaneous (SC) injection a total of four times (3 mg of tamox-
ifen on day 1, followed by 2 mg of tamoxifen on days 2, 3, and 4).
This latter induction regime was well tolerated. However, a sub-
set of male mice in our aged induced cohorts reached an unex-
pected early clinical end point at ∼60 d after induction due
to unresolved hernias as has been previously described (Ma
et al. 2015). This outcome was MDM2 and CreER genotype-
independent.
For total body irradiation (TBI) experiments,micewere induced
via the SC tamoxifen method and left for a total of 10 d from the
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first injection before proceedingwith TBI. Theywere then treated
with either 6 or 8 Gy TBI from an Xstrahl RS225 Cabinet X-ray
Irradiator (Xstrahl) as indicated and sampled at the time points af-
ter TBI noted in the manuscript.
Liver function assays (ALT/AST)
ALT and AST activity were determined in EDTA-treated plasma
using the Alanine Transaminase Activity Assay Kit (ab105134)
and the aspartate aminotransferase activity assay kit (ab138878)
fromAbcam. Both assayswere performed following themanufac-
turer’s recommendations. Samples were run together, analyzed
in triplicate wells per mouse sample, and themean value of these
technical replicates was used for subsequent analysis.
Pancreatic function assay (lipase)
Lipase activity was determined in EDTA-treated plasma using
the lipase assay kit from Abcam (ab118969), according to the
manufacturer’s recommendations. Samples were run together,
analyzed in triplicate wells per mouse sample, and the mean val-
ue of these technical replicates was used for subsequent analysis.
Long-term mouse weights
Mice were weighed prior to the start of the SC tamoxifen induc-
tion regime and then periodically thereafter. During the induc-
tion protocol and shortly afterward, mice were weighed at least
daily. Over the longer aging experiment, mice were monitored
andweighed every other day.Mouseweights relative to the initial
baseline were then plotted.
Immunohistochemistry (IHC)
All IHC staining was performed on 4-μm formalin-fixed paraffin
embedded (FFPE) sections that had previously been warmed for
2 h at 60°C. Slides were deparaffinized and rehydrated according
to the relevant staining platform for each antibody as noted in
the accompanying reagent and antibody information tables (Sup-
plemental Tables S1,S2). Manual staining for MDA was per-
formed as described previously (Humpton et al. 2018).
For staining on the Dako Autostainer Link 48 (Agilent), FFPE
sections underwent manual dewaxing and rehydration through
xylene and a graded ethanol series.Heat-induced epitope retrieval
(HIER) was then performed on a Dako PT module where the
sections were heated for 20min to 97°C using target retrieval sol-
ution (TRS), high pH (Agilent). The sections underwent peroxi-
dase blocking (Agilent) before application of primary antibody
for 40min at a previously optimized dilution. Secondary antibody
incubation and downstream signal detection were performed us-
ing the rabbit envision secondary antibody for 30 min and liquid
DAB (both Agilent).
For staining on the Leica Bond Rx autostainer, sections were
loaded onto the autostainer and underwent dewaxing using
Bond dewax solution and epitope retrieval using either ER2 buffer
for 20 min at 95°C or enzyme 1 (Enz1) for 10 min at 37°C, as in-
dicated (dewaxing and retrieval both done on-board; all reagents
from Leica). Sections were rinsed with Leica wash buffer before
undergoing peroxidase block for 5 min using an Intense R kit
(Leica). Sectionswere incubatedwith a previously optimized con-
centration of primary antibody for 30min. Secondary antibody in-
cubation was performed using either the rabbit envision
secondary antibody kit (Agilent) or Rat ImmPRESS secondary an-
tibody kit (Vector labs) as appropriate for 30 min, and signal was
visualized with DAB using the Intense R kit (Leica).
After detection in either system or manually, sections were
counterstained with haematoxylin and coverslipped using DPX
mountant (CellPath) prior to analysis.
Analysis of IHC images
The analysis of IHC staining for all stains except phospho-H2AX
was performed as previously described (Humpton et al. 2018). A
minimum of five random nonoverlapping 20X magnification im-
ages were taken from each IHC slide using an Olympus BX51mi-
croscope with Zen Blue software (Zeiss). From these images, the
positive staining per slide was calculated using ImageJ software.
For quantification of phospho-H2AX, positive acinar cells, or he-
patocytes (pancreas/liver) per 20× field from the five images per
mouse were quantified by hand and the mean value per mouse
was reported in the relevant figures.
Cell culture
MEF and BMK cells were generated as described below. Stock
flasks of cells were maintained in DMEM high-glucose medium
containing pyruvate (Gibco 21969035) supplemented with
2 mML-glutamine, penicillin/streptomycin, gentamycin, and ei-
ther 10% FBS (MEFs) or 5% FBS and ITS liquid medium supple-
ment (BMK cells; Sigma Aldrich). Cells were cultured at 37°C
in a humidified atmosphere of 5% CO2. Mycoplasma testing
was not performed on these primary cell lines.
BMK cells
BMK primary cells were isolated and cultured as previously de-
scribed (Degenhardt et al. 2002). Briefly, the kidneys from 4 to
5-d-old baby mice were minced with 1.5 mL of collagenase
(0.1 U/mL)/dispase (0.8 U/mL) solution and incubated for 40
min at 37°C. After incubation, single cells were isolated from
the solution and cultured in DMEM supplemented with 5%
FBS, 2 mM L-glutamine, penicillin/streptomycin, gentamycin,
and ITS liquid medium supplement (Sigma I3146).
In all experiments with BMK cells, the expression of the
Mdm2I438K allele was induced by infection with recombinant ad-
enovirus expressing empty vector control or Cre Recombinase for
24 h. After infection, themediumwas changed and cells were left
for 5 d. Theywere then treatedwith compounds (e.g., 4 μMNutlin
dissolved in DMSO for 8 h) and analyzed as indicated.
Recombinant adenoviruswas purchased from theUniversity of
Iowa gene therapy core facility.
MEFs
PrimaryMEFs were isolated as previously described from embry-
onic day E14.5 embryos (Humpton et al. 2019). The p53 WT and
p53KO/KO MEFs used in Supplemental Figure S1 were generated
from either ArfKO/KO mice (p53 WT) or p53KO/KO mice and
were provided by Daniel Murphy (p53 WT) or Stephen Jones
(p53 KO). p53KO/KO; Mdm2KO/KO double knockout MEFs in Sup-
plemental Figure S1, E–G, were created from p53KO/KO;
Mdm2KO/KO mice and were provided by Stephen Jones. MEFs
were cultured in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, penicillin/streptomycin and gentamycin.
In all experiments with the CreER-inducible MEFs, the expres-
sion of theMdm2I438K allele was induced by treatment with 1 μM
4-OHT dissolved in ethanol (Sigma H6278) for 48 h. After induc-
tion, themediawas changed and cells were left for an additional 3
d. The MEFs were then treated with compounds (e.g., 4 μM Nut-
lin for 8 h) and analyzed as indicated.
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MDM2 and p53 plasmids
Mouse p53 andmouseMdm2 pcDNA3.1 plasmidswere previous-
ly described (Lee et al. 2015). The mCherry plasmid (pmCherry-
C1) was also previously described (Werner et al. 1996). Themouse
Mdm2 mutant plasmids were generated from the WT mouse
Mdm2 plasmid using site-directed mutagenesis PCR as previous-
ly described (Nomura et al. 2017). The resulting Mdm2 mutant
plasmids were verified by DNA sequencing prior to use. Mouse
FLAG-MDM4 was a gift from Jean-Christophe Marine. Plasmids
are listed in Supplemental Table S3.
p53 degradation assay
WT MEFs were transfected with the two pcDNA3.1 plasmids
containing mouse Trp53 and the indicated mouse Mdm2 con-
structs, respectively, as well as the mCherry plasmid
(pmCherry-C1), using GeneJuice (Novagen) following the manu-
facturer’s recommendations. Briefly, a mixture of DNA plasmids
(in a 1:1:1 ratio) and GeneJuice in OptiMEMwas added dropwise
to cell culture plates that had been seeded the day before. Reagent
volumes, cell numbers, and DNA content were scaled according
to plate size within the manufacture’s recommended ranges.
Cells were incubated for 24 h with the transfectionmixture to al-
low for plasmid expression and then the degradation of p53 rela-
tive to mCherry was assessed through Western blot analysis.
Cell cycle analysis
Previously induced BMKcellswere treatedwithDMSOorH2Oas
vehicle control or with 4 μM Nutlin dissolved in DMSO (Sigma
N6287) or 1 μM doxorubicin dissolved in H2O (Sigma 324380)
for 8 h. The cells were then harvested with trypsin-EDTA,
washed in cold PBS, and fixed in ice-cold 70% ethanol for at least
30 min at 4°C. Prior to analysis, cells were rehydrated with PBS
and treated with 50 µg/mL RNase A in PBS for at least 15 min.
DNAwas stainedwith propidium iodide (PI) before flow cytomet-
ric analysis (Attune NxT, Thermo Fisher Scientific). DNA con-
tent was analyzed in channel FL2 and the percentage of cells in
each phase was determined by DNA content analyzed by FlowJo
10 software (FlowJo) based on the Watson Pragmatic algorithm
(Watson et al. 1987).
Cell growth assay
MEFs were treated with 1 μM 4-OHT in medium for 48 h to in-
duce expression of the Mdm2I438K allele. The medium was re-
placed and MEFs were left for an additional 3 d. On day 5, MEFs
were treated with DMSO or H2O as vehicle control or with
4 μM Nutlin or 1 μM doxorubicin for a period of 48 h. The medi-
um was replaced with normal culture medium after 48 h. At the
indicated time points (days 0, 2, 5, 7, 10), cells were trypsinized,
resuspended in PBS-EDTA, and counted with a CASY Model
TT Cell Counter (Innovatis, Roche Applied Science). Relative
cell growth was calculated as the fold change from the baseline
day 0 count for each condition.
Quantitative RT-PCR
RNA was extracted from BMK and MEF cells using the Qiagen
RNeasy mini kit or NEB Monarch Total RNA miniprep kit and
treated with RNase-free DNase (Qiagen or NEB) prior to cDNA
synthesis, both according to the manufacturer’s recommenda-
tions. cDNA was synthesized using either the high-capacity
RNA-to-cDNA kit (Thermo Scientific) or LunaScript RT Super-
Mix kit (NEB). The qPCR reaction was performed on an ABI
7500 Fast system (Thermo Scientific) or QuantStudio 7 Flex
real-time PCR system (Applied Biosystems) using either Fast
SYBR GGreen master mix (Thermo Scientific) or PowerUp
SYBR Green master mix (Applied Biosystems) according to the
manufacturer’s recommendations and the primers listed in Sup-
plemental Table S4A. Gene expression was quantified relative
to the housekeeping gene B2m according to the comparative
ΔΔCt method.
For qPCR analysis of p53 targets in mouse tissue samples, liver
and duodenumwere first isolated and preserved in Allprotect tis-
sue reagent (Qiagen). Tomake RNA, tissue was homogenized us-
ing a Precellys tissue homogenizer (Bertin Instruments) and RNA
was extracted using the AllPrep DNA/RNA mini kit (Qiagen),
both according to the manufacturers’ recommendations. The re-
sulting DNAwas analyzed for recombination as described below.
cDNA was synthesized using the high-capacity RNA-to-cDNA
kit (Thermo Scientific). The qPCR reaction was performed on a
QuantStudio five real-time PCR system (Thermo Scientific) us-
ing TaqMan FAST advanced master mix and Taqman gene ex-
pression assays (all Thermo Scientific) according to the
manufacturer’s recommendations and using the assays listed in
Supplemental Table S4B. Gene expressionwas quantified relative
to the housekeeping gene Actin according to the comparative
ΔΔCt method.
Genotyping PCR
For Mdm2I438K MEF and BMK cells and embryos, genomic DNA
was isolated as previously described (Wang and Storm 2006).
DNAwas amplified using KOD hot start PCRmaster mix (Nova-
gen) according to the manufacturer’s recommendations. PCR
primers were designed using the Primer BLAST tool (NCBI) and
are listed in Supplemental Table S5.
For genotyping of day E12.5 embryos where histology was ex-
amined, genomic DNA was isolated using the AllPrep DNA/
RNA FFPE kit (Qiagen) according to the manufacturer’s recom-
mendations. DNAwas then amplified as for MEFs and BMK cells
above.
For recombination PCRs, genomic DNA was isolated from
mouse liver and duodenum alongside RNA using the AllPrep
DNA/RNA mini kit (Qiagen) as described above. DNA was am-
plified using KAPA2G Fast HotStart genotyping mix according
to standard protocols. PCR primers for genotyping and recombi-
nation PCRs were designed using the Primer BLAST tool
(NCBI) and are listed in Supplemental Table S5.
Western blotting
Standard procedures were followed for Western blotting. Briefly,
proteins were extracted with cell lysis buffer supplemented
with EDTA-free Mini-Complete protease inhibitors and a Phos-
STOP phosphatase inhibitor cocktail (Roche). Protein lysates
were clarified and separated using 4%–12% Bis-Tris NuPAGE
gels (Thermo Fisher) and then transferred onto nitrocellulose
membranes (GE Healthcare). Membranes were blocked with Od-
yssey blocking buffer (LI-COR) or 5% dried skimmed milk in
TBS-T and incubated with primary antibodies overnight rocking
at 4°C. To develop the blots, the membrane was incubated with
appropriate IRDye 680LT-conjugated or IRDye 800CW-conjugat-
ed secondary antibodies for 1 h before detection using anOdyssey
scanner (LI-COR). Images were analyzed using Image Studio soft-
ware (LI-COR). Alternatively, membranes were incubated with
appropriate HRP-linked secondary antibodies (CST) and devel-
opedusing Pierce ECLWestern Blotting Substrate (ThermoFisher
Scientific) and chemiluminescence films (GE Healthcare).
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ACTINwas used as a loading control performed on the same blot
as the other panels shown in each figure. Primary and secondary
antibodies used for Western blotting are listed in Supplemental
Tables S6A and S7.
Coimmunoprecipitation
MEFs were transfected with various plasmid pairs (listed in Sup-
plemental Table S3) in a 1:1 ratio using jetPRIME (Polyplus
Transfections) transfection reagent according to the manufactur-
er’s instructions. Twenty-four hours after transfection, cells were
treated with 10 µM proteasome inhibitor MG-132 (Sigma-Al-
drich) for 4 h. Subsequently, protein isolation was carried out us-
ing cell lysis buffer (150 mM NaCl, 50 mM Tris-HCl at pH 8.0,
1% Triton X-100) supplemented with protease inhibitor (Roche)
(30-min incubation at 4°C followed by two freeze–thaw cycles).
From each lysate, an aliquotwas saved for input analysis byWest-
ern blotwhile the remaining lysatewas incubatedwith the appro-
priate antibody (Supplemental Table S6B) on a rotating wheel
overnight at 4°C. The next day, 20 µL of Dynabeads Protein G
for immunoprecipitation (ThermoFisher Scientific) was added
to each lysate followed by a 2-h incubation on a rotating wheel
at 4°C. The samples were washed twice with cell lysis buffer be-
fore the immunoprecipitates were eluted from the beads with
NuPAGE LDS sample buffer (Invitrogen). Samples were boiled
for 10min at 98°C and then loaded on 4%–12%Bis-TrisNuPAGE
gels (Thermo Fisher). Western blotting was carried out as de-
scribed above with appropriate primary antibodies and HRP-
linked rabbit anti-mouse IgG (light chain-specific [CSL]) second-
ary antibody followed by chemiluminescent detection. Antibod-
ies used for immunoprecipitation are listed in Supplemental
Table S6B.
Protein purification
Mouse MDM2 417–C WT and I438K were cloned into pGEX4T1
vector with a N-terminal GST-tag followed by a TEV cleavage se-
quence and expressed in Escherichia coli BL21(DE3) GOLD.Cells
were grown in Luria Bertanimedium to anOD600 of 0.6–1.0 at 37 °
C and induced with 0.2 mM isopropyl-β-D-1-thiogalactopyrano-
side for 16–20 h at 20°C. Cells were lysed in 50 mM Tris-HCl
(pH 7.6), 0.4 MNaCl, 1 mMDTT, and 2.5 mM phenylmethylsul-
fonyl fluoride. GST-MDM2 variants were purified by glutathione
Sepharose (GE Healthcare) affinity chromatography followed by
gel filtration chromatography. Human UBA1 and fluorescently
labeled ubiquitin (Ub) were purified as described previously (Mag-
nussen et al. 2020). The stable UbcH5B-Ub conjugate used in the
surface plasmon resonance (SPR) analyses was generated by link-
ing the C terminus of Ub to the catalytic C85S of UbcH5B C85S
as described previously (Dou et al. 2012). All protein concentra-
tions were determined by absorbance at 280 nm for Ub and Bio-
Rad protein assay with BSA as a standard for other proteins.
SPR binding analyses
SPR experiments were performed at 25°C on a Biacore T200 in-
strument using a CM-5 chip (GE Healthcare) with coupled anti-
GST antibody as described previously (Magnussen et al. 2020).
Briefly, GST-mouse MDM2 variants were coupled on the chip
and a serial dilution of UbcH5B-Ub in running buffer containing
25 mMTris-HCl (pH 7.6), 150 mMNaCl, 0.1 mg/mL BSA, 1 mM
DTT, and 0.005% (v/v) Tween-20 was used as analyte. Two tech-
nical replicates were performed. The data were analyzed using
Biacore T200 BIAevaluation (GE Healthcare) and Scrubber2 (Bio-
Logic Software).
In vitro autoubiquitination assay
UbcH5B (7 μM) was precharged with UBA1 (0.2 μM) and fluores-
cently labeled Ub (70 μM) for 30 min at 23°C in buffer containing
50 mM Tris-HCl (pH 7.6), 50 mM NaCl, 5 mM ATP, and 5 mM
MgCl2. Autoubiquitination reaction was initiated by adding
GST-mouse MDM2 417-C variants (0.7 μM) or buffer alone and
stopped at the indicated time-point by addingNuPAGELDSSam-
ple Buffer supplemented with 100 mM DTT. All concentrations
in the parentheses indicated final protein concentration in the re-
action. The reaction products were separated by SDS-PAGE and
ubiquitinated proteins were detected using an Odyssey CLx im-
aging system (LI-COR Biosciences). The SDS-PAGE was then
stained with Coomassie for visualization of E3 loading.
Data plotting and statistical analysis
Data were plotted using Prism 7 (GraphPad). The statistical anal-
ysis for each experiment was performed using the test indicated
in the relevant figure legend and multiplicity adjusted P-values
using the built-in analysis tools of Prism 7. Figures were prepared
using Illustrator (Adobe). Unless otherwise indicated, data are
represented as mean± standard error of the mean (SEM) for error
bars. Asterisks denote P-value as follows: P < .05 (∗), P< .01 (∗∗),
P< .001 (∗∗∗), and P< .0001 (∗∗∗∗).
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CORRIGENDUM
Genes & Development 35: 117–132 (2021)
Corrigendum: Differential requirements for MDM2 E3 activity during embryogenesis
and in adult mice
Timothy J. Humpton, Koji Nomura, Julia Weber, Helge M. Magnussen, Andreas K. Hock, Colin Nixon,
Sandeep Dhayade, David Stevenson, Danny T. Huang, Douglas Strathdee, Karen Blyth, and Karen H. Vousden
In the above-mentioned paper, the authors describe the generation of Cre-inducible Mdm2I438K/I438K mice derived from
mice carrying the tm1.1 allele (Supplemental Fig. S1H). In fact, these mice were generated using the tm1 allele, which
is identical to the tm1.1 allele but retains the Neomycin resistance (Neo) cassette (Supplemental Fig. S1H). This has
now been corrected in the article online. The Neo cassette is lost during Cre-induced recombination and the tm1.2 allele
(Supplemental Fig. S1H) remains as described in the paper. The authors apologize for this error, which does not alter any of
the results presented in the study.
doi: 10.1101/gad.348692.121
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